PRESS RELEASES

Date Title and Summary View
Sep 19, 2017
Summary ToggleZafgen to Present at the 2017 Ladenburg Thalmann Healthcare Conference
BOSTON , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes , Ph.D., President
Summary ToggleZafgen to Present at the 2017 Ladenburg Thalmann Healthcare Conference
Sep 12, 2017
Summary ToggleZafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
-Company Expects to Report Interim Data from ZAF-1061-201 in First Half of 2018- BOSTON , Sept. 12, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), today announced initiation of ZAF-1061-201, the Company’s Phase 2 clinical trial evaluating ZGN-1061 in patients with type 2 diabetes.
Summary ToggleZafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
Sep 12, 2017
Summary ToggleZafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- Data Demonstrate Dose-Dependent Beneficial Impact of ZGN-1061 on Glucose Tolerance, Body Weight and Cardiometabolic Markers- -Improvements in Glycemic Control Independent of Weight Loss- BOSTON , Sept. 12, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), today announced the presentation of
Summary ToggleZafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Aug 8, 2017
Summary ToggleZafgen Reports Second Quarter 2017 Financial Results
-ZGN-1061 Phase 1 Data Support Continued Development for Obese Patients with Type 2 Diabetes- -Company to Initiate Phase 2 Clinical Trial in Third Quarter of This Year- -Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $106 Million ; Increases Year-End Cash Guidance to Greater
Summary ToggleZafgen Reports Second Quarter 2017 Financial Results
Aug 2, 2017
Summary ToggleZafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
BOSTON , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes , Ph.D., President
Summary ToggleZafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
Aug 1, 2017
Summary ToggleZafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results
BOSTON , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that it will host a conference call on
Summary ToggleZafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results
Jun 13, 2017
Summary ToggleZafgen to Present at the JMP Securities Life Sciences Conference
BOSTON , June 13, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes , Ph.D., President
Summary ToggleZafgen to Present at the JMP Securities Life Sciences Conference
Jun 10, 2017
Summary ToggleZafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association's 77th Annual Scientific Sessions
-Successful Phase 1 Clinical Trial Garners Late-Breaking ADA Presentation and Supports Advancement to Phase 2 Development- -ZGN-1061 Treatment Improves Glycemic Control and Body Weight in Preclinical Models- -Data Highlight Favorable Safety and Tolerability Profile- BOSTON , June 10, 2017 (GLOBE
Summary ToggleZafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association's 77th Annual Scientific Sessions
Jun 6, 2017
Summary ToggleZafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions
-Clinical Abstract will provide full data set from ZGN-1061 Phase 1 Clinical Trial- -Preclinical Abstract will present results for ZGN-1061 on glycemic control, weight loss and safety profile- BOSTON, June 06, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today announced two late-breaking
Summary ToggleZafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions
May 9, 2017
Summary ToggleZafgen Reports First Quarter 2017 Financial Results
-ZGN-1061 Phase 1 Data Support Continued Development; On Track to Initiate Phase 2 Clinical Trial in Patients with Type 2 Diabetes in Second Half of This Year- BOSTON, May 09, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), today announced its first quarter 2017 financial results.
Summary ToggleZafgen Reports First Quarter 2017 Financial Results